Virus‐Mimic mRNA Vaccine for Cancer Treatment.
- Published in:
- Advanced Therapeutics, 2021, v. 4, n. 11, p. 1, doi. 10.1002/adtp.202100144
- By:
- Publication type:
- Article
Works matching AU Tian, Shaohui
Results: 7
1
2
CuO nanoparticles for glioma treatment in vitro and in vivo.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-74546-7
- By:
- Publication type:
- Article
3
EPIC-0307-mediated selective disruption of PRADX–EZH2 interaction and enhancement of temozolomide sensitivity to glioblastoma via inhibiting DNA repair and MGMT.
- Published in:
- Neuro-Oncology, 2023, v. 25, n. 11, p. 1976, doi. 10.1093/neuonc/noad102
- By:
- Publication type:
- Article
4
Identification of an Aptamer With Binding Specificity to Tumor-Homing Myeloid-Derived Suppressor Cells.
- Published in:
- Frontiers in Pharmacology, 2022, v. 12, p. 1, doi. 10.3389/fphar.2021.752934
- By:
- Publication type:
- Article
5
Omics-based integrated analysis identified ATRX as a biomarker associated with glioma diagnosis and prognosis.
- Published in:
- Cancer Biology & Medicine, 2019, v. 16, n. 4, p. 784, doi. 10.20892/j.issn.2095-3941.2019.0143
- By:
- Publication type:
- Article
6
lncRNA PRADX is a Mesenchymal Glioblastoma Biomarker for Cellular Metabolism Targeted Therapy.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.888922
- By:
- Publication type:
- Article
7
RUNX1 (RUNX family transcription factor 1), a target of microRNA miR-128-3p, promotes temozolomide resistance in glioblastoma multiform by upregulating multidrug resistance-associated protein 1 (MRP1).
- Published in:
- Bioengineered, 2021, v. 12, n. 2, p. 11768, doi. 10.1080/21655979.2021.2009976
- By:
- Publication type:
- Article